Targeting GPCRs, Ab Initio

Ab Initio Biotherapeutics Inc. is using its biochemistry expertise and an integrated set of three platforms to purify GPCRs in clinically relevant conformations for producing anti-GPCR antibodies.

Antibodies can act on their targets with better specificity than small molecules, but high conformational variability and difficulties accessing homogeneous GPCR antigens have made it hard to find physiologically relevant epitopes. ...